U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07210632) titled 'Window Trial of Fluorescently Labeled Nivolumab (Nivo800) in High Grade Glioma (HGG)' on Sept. 29.
Brief Summary: High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imaging-enabled formulation of nivolumab-nivo800-which incorporates a near-infrared fluorescent dye to enable real-time visualization of drug distribution within tumor tissue.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIO...